Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Sodium-glucose Cotransporter 2 (SGLT2) Inhibitor”

26 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 26 results

Testing effectiveness (Phase 2)Study completedNCT03316131
What this trial is testing

Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA

Who this might be right for
Asymptomatic Hyperuricemia
AstraZeneca 36
Post-approval studies (Phase 4)Not Yet RecruitingNCT07482943
What this trial is testing

The Effect of Dapagliflozin on Exercise and Cardiac Functional Status of Patients After Fontan Procedure

Who this might be right for
FontanHeart FailureDapagliflozin+2 more
The University of Hong Kong 30
Testing effectiveness (Phase 2)UnknownNCT04419337
What this trial is testing

Pioglitazone and SGLT2 Inhibitors vs. DPP4 Inhibitors in Patients With Stroke

Who this might be right for
Diabetes MellitusStroke
Chang Gung Memorial Hospital 200
Not applicableStudy completedNCT02500186
What this trial is testing

The Clinical Study to Assess the Effect of the Amount of Carbohydrate Intake and Meals Differing in Glycemic Index (GI) in Patients Treated With a Sodium-dependent Glucose Cotransporter 2 (SGLT2) Inhibitor

Who this might be right for
Diabetes Melltius, Type 2
Kansai Electric Power Hospital 24
Post-approval studies (Phase 4)Looking for participantsNCT06972732
What this trial is testing

A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes

Who this might be right for
Type 2 Diabetes
Boryung Pharmaceutical Co., Ltd 204
Testing effectiveness (Phase 2)Study completedNCT05232071
What this trial is testing

Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus

Who this might be right for
NASH - Nonalcoholic SteatohepatitisDiabetes Mellitus, Type 2
Inventiva Pharma 42
Post-approval studies (Phase 4)Study completedNCT02360774
What this trial is testing

Mechanisms of Weight Loss With SGLT2 Inhibition

Who this might be right for
Type 2 DiabetesOverweightObesity
Beth Israel Deaconess Medical Center 30
Not applicableStudy completedNCT06453161
What this trial is testing

Pre-operative Exposure to SGLT2 Inhibitors and Post-operative Acute Renal Failure in Cardiac Surgery: a Retrospective Monocentric Cohort Study

Who this might be right for
Acute Kidney InjuryCardiacSurgery
Hospices Civils de Lyon 500
Post-approval studies (Phase 4)UnknownNCT05975528
What this trial is testing

Effect of Sodium-glucose Cotransporter-2 Inhibitor in Cellular Senescence in Patients With Cardiovascular Diseases or Type 2 Diabetes

Who this might be right for
Diabetes MellitusCellular SenescenceSodium-Glucose Transporter 2 Inhibitors
Yonsei University 92
Large-scale testing (Phase 3)Study completedNCT05283057
What this trial is testing

Empagliflozin in Patients With Glomerulonephritis

Who this might be right for
GlomerulonephritisProteinuria
Kasr El Aini Hospital 50
Not applicableStudy completedNCT07269197
What this trial is testing

Association of SGLT2 Inhibitors Therapy With Elastographic and Molecular Markers of Liver Injury in Type 2 Diabetes

Who this might be right for
Non-Alcoholic Fatty Liver DiseaseDiabetes Mellitus, Type 2
Josip Juraj Strossmayer University of Osijek 67
Large-scale testing (Phase 3)Not Yet RecruitingNCT07417306
What this trial is testing

HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor

Who this might be right for
Type 2 Diabetes
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. 912
Post-approval studies (Phase 4)Active Not RecruitingNCT06933355
What this trial is testing

Acute Effects of SGLT2 Inhibitor on Kidney Allograft Oxygen Tension

Who this might be right for
Kidney Transplantation RecipientsMagnetic Resonance Imaging (MRI)Sodium-Glucose Transporter 2 Inhibitors+3 more
Odense University Hospital 8
Post-approval studies (Phase 4)Study completedNCT05233163
What this trial is testing

SGLT2 Inhibitors in Transthyretin Amyloid Cardiomyopathy

Who this might be right for
Transthyretin Amyloid Cardiomyopathy
Columbia University 15
Post-approval studies (Phase 4)Active Not RecruitingNCT05590143
What this trial is testing

ProMoting Effective Renoprotection in Cardiac sURgery Patients by Inhibition of SGLT-2

Who this might be right for
Acute Kidney InjuryCardiac SurgerySodium-Glucose Transporter 2 Inhibitor
Amsterdam UMC 784
Early research (Phase 1)Study completedNCT06828731
What this trial is testing

Evaluation of Empagliflozin vs Standard Care in Veterans With Prediabetes

Who this might be right for
Prediabetes
Charles George VA Medical Center 60
Not applicableStudy completedNCT02966626
What this trial is testing

A Real World Experience of Dapagliflozin in Type 2 Diabetes

Who this might be right for
Type2 Diabetes
University of Malaya 223
Post-approval studies (Phase 4)Looking for participantsNCT06668389
What this trial is testing

Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary Status Trial

Who this might be right for
Congenital Heart DiseaseRepaired Tetralogy of Fallot (rTOF)Pulmonary Regurgitation+2 more
The University of Hong Kong 106
Early research (Phase 1)Study completedNCT03852901
What this trial is testing

Sodium-glucose Co Transporter 2 (sGLT2) Inhibitor and Endogenous Ketone Production

Who this might be right for
EmpaglifozinPhysiological Effects of DrugsHypoglycemic Agents+1 more
National Institute on Aging (NIA) 21
Large-scale testing (Phase 3)Ended earlyNCT03933956
What this trial is testing

Metabolic Effects of the SGLT-2 Inhibitor Empagliflozin in Patients With Diabetic Nephropathy (MEDiaN)

Who this might be right for
Diabetic Nephropathies
Singapore General Hospital 2
Load More Results